Integral Diagnostics (IDX) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional land owners and confirmation of quorum.

• Hybrid format enabled in-person and virtual participation, with voting and Q&A procedures explained.

• Board members, auditors, management, and advisors introduced.

Financial performance review

• FY25 revenue grew 33.7% to $628 million, with operating EBITDA margin at 22.0%.

• Operating EBITDA rose from AUD 85.2m in FY22 to AUD 140.0m in FY25.

• Operating diluted EPS increased 32.9% to 10.2 cents; final dividend per share was $0.212.

• Merger with Capital Health delivered $7 million in cost synergies in FY25, with $40 million annualized expected.

• Net debt to EBITDA reduced to 2.6x (2.4x pro forma), reflecting a stronger balance sheet.

Board and executive committee updates

• Three new directors joined: Laura McBain, Dr. Kevin Shaw, and Dr. Manish Mittal, bringing diverse expertise.

• Two new Non-Executive Directors joined the Board from Capitol Health.

• Appointment of a Radiologist Director to ensure specialist medical input in decision-making.

• CEO Dr. Ian Kadish announced retirement at end of FY26; board is finalizing recruitment for his successor.